CSG/TELENOR-DENMARK
23.7.2024 08:31:33 CEST | Business Wire | Press release
Telenor Denmark, the second-largest mobile operator in the Danish market, is a trailblazer for customer-first innovation. To reinforce its position at the forefront of digital telecommunications commerce and continue to provide excellent customer experiences, Telenor Denmark chose CSG®‘s (NASDAQ: CSGS) cloud-native, software-as-a-service (SaaS) platforms to drive its evolution into the future. This transformation turbocharges Telenor Denmark’s omnichannel monetisation, improves business efficiency and future-proofs the B2C and B2B customer experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722892898/en/
“At Telenor Denmark, we make it easy for our 1.7 million customers to connect with the people and services that matter most to them. This is how we earned the industry’s highest customer satisfaction in 2023,” said Lars Thomsen, CEO, Telenor Denmark. “As we look to the future, we must adapt to meet fluctuating demands and continue to offer new, innovative solutions to our customers. CSG has the proven track record, industry depth and cloud expertise we need to embrace end-to-end digitalisation that will further strengthen our ability to deliver excellent customer service and inspire our customers. It’s an exciting time for Telenor Denmark and this strategic collaboration with CSG brings us one step closer to the future we want to shape for our customers, partners and ourselves.”
As Telenor Denmark and CSG collaborate to make the communication service provider (CSP) a leading digital telco in Denmark, CSG Ascendon, a market-leading AWS cloud-native revenue management platform, with pre-integrated, world-class customer engagement capabilities powered by CSG Xponent, enhance Telenor Denmark’s growth with flexibility, efficiency and intelligence. With CSG’s real-time decisioning engine, Telenor Denmark will deliver better digital experiences across all touchpoints, enhance omnichannel support for all business segments and seize new revenue opportunities. Along with CSG’s industry-leading configure, price and quote capabilities, the two platforms give Telenor Denmark powerful tools to seamlessly bundle offers with partners and create faster, more efficient solutions for its business customers. These improvements make it easy for Telenor Denmark to keep happier, more loyal customers that drive faster revenue for future innovation.
“To come out on top in digital telco commerce, CSPs need business infrastructure that allows them to hit the ground running and wow customers with speed, sophistication and flexibility,” said Ian Waterson, SVP of Go-To-Market, CSG. “As a customer satisfaction leader, Telenor Denmark understands the importance of customer loyalty in driving long-term growth. Their trust in CSG and our industry-leading solutions will elevate customer experience and set Telenor Denmark up for future-ready success.”
Get the facts on CSG Ascendon’s B2C, B2B and B2B2X capabilities and read CSG’s eBook to discover how you can make your CX more proactive, predictive and personalised with data-driven customer communication programs.
About CSG
CSG empowers companies to build unforgettable experiences, making it easier for people and businesses to connect with, use and pay for the services they value most. Our customer experience, billing and payments solutions help companies of any size make money and make a difference. With our SaaS solutions, company leaders can take control of their future and tap into guidance along the way from our fiercely committed and forward-thinking CSGers around the world.
Want to be future-ready and a change-maker like the global brands that trust CSG? Visit csgi.com to learn more.
About Telenor Denmark
Telenor helps Danes create good connections through mobile and internet services. We are committed to being the telecommunications company that provides Danish businesses and consumers with a secure, straightforward, and safe digital everyday life. Therefore, we invest massively in innovation and in developing the Danish telecommunications infrastructure and have recently completed the 5G modernization of our nationwide mobile network.
Telenor is Denmark's second-largest mobile operator and a part of the Telenor Group, operating throughout Scandinavia and Asia. Globally, we assist 186 million customers in their communication needs. In Denmark, we have approximately 1000 employees and 38 stores spread across the country.
You can learn more about us at www.telenor.dk.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722892898/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom